THE INDUSTRY'S PUREST INHALANT-QUALIFIED CHITOSAN
TRŪ CHITOSAN USP
INHALANT: A BREAKTHROUGH IN PHARMACEUTICAL-
GRADE PURITY
Introducing USP
Inhalant trū Chitosan
For decades, researchers have explored chitosan’s application in inhaled drug delivery therapies, with over 25,000 published studies—4,500 in 2024 alone. Until now, a major challenge remained: a chitosan pure enough for safe and effective inclusion for inhalant drug delivery.
presents
trū® Chitosan is the first cGMP-compliant chitosan that not only meets USP-NF monograph standards but also conforms to the demanding USP 232 impurity limits required for inhalant drug delivery.
Produced in an FDA-registered facility, trū Chitosan production is linear, tissue to chitin to chitosan, with positively no blending resulting in unimodal distribution curve of molecular weight and a narrow Polydispersity Index (PDI) ensuring that researchers and producers finally have a scaled, ultra-pure, consistent chitosan for inhaled delivery.
"trū Chitosan USP Inhalant fulfills the promise of decades of research. Our objective is quite simple—manufacture and offer the world’s finest chitosan to the global medical community for research, clinical trials, and pharmaceutical and medical device production."
MICHAEL ZIEBELL
Chief Operating Officer, trū Chitosan
TRŪ CHITOSAN USP INHALANT
UNPARALLELED
PURITY & COMPLIANCE
USP Inhalant trū® Chitosan sets a new benchmark for safety, consistency, and pharmaceutical readiness:
REGULATORY READY
USP-NF, USP 232, cGMP, FDA Registered Facility, Certificate of Analysis, and industry first, complete chain-of-custody Certificate of Origin.
UNMATCHED PURITY
Ubiquitous heavy metals (Pb, Hg, Cd, As) typical assay are below Level of Quantification (LOQ) or undetectable.
-
Typical Assay of Ni 0.41 ppm (USP 232 ≤ 0.6 ppm)
-
Typical Assay of Cr 0.03 ppm (USP 232 ≤ 0.3 ppm)
-
Typical Assay Tropomyosin (Allergen Protein) <1 ppm or below LOQ
CUSTOM CHARACTERIZATIONS
-
H-NMR measured DDA% 70-95%
-
GPC measured Mw options.
-
Ultra-Low & Low Endotoxin Content Options
“In over 40 years of working with the chitosan molecule, I cannot believe we are seeing this happen, a truly perfect chitosan. I have never seen anything like trū Chitosan.”
SAMUEL HUDSON, Ph.D.
Professor Emeritus, North Carolina State University and globally renown expert on the Chitosan molecule.
“The exoskeleton raw material harvested from trū Chitosan’s captive shrimp production is so consistent and free of impurities it provides the near perfect platform from which the Parimer team developed the innovative cGMP processes to reach the USP 232 inhalant delivery qualifications. Very satisfying work. ”
RICHARD PACE, Ph.D.
Founder & Chief Science Officer, Parimer Scientific
CMO Partner at trū Chitosan
WHAT CAN TRŪ CHITOSAN INHALED THERAPIES DO?
With scientific validation from thousands of
studies, chitosan is unlocking new possibilities in:
APPLICATIONS & USE
ENHANCED
DRUG DELIVERIES
20,100 STUDIES
Mucoadhesive properties increase drug retention, prolong release, and enhance bioavailability.
ANTI-MICROBIAL
THERAPY
19,100 STUDIES
Antibacterial and antiviral properties enable targeted delivery of antimicrobial agents for bacterial, viral, or fungal infections, asthma, cystic fibrosis, and respiratory diseases, including cancer.
ANTI-INFLAMMATORY
EFFECTS
15,400 STUDIES
Modulates immune responses, potentially reducing inflammation linked to asthma and other respiratory conditions.
CANCER
TREATMENT
19,500 STUDIES
Chitosan-based nanoparticles carry chemotherapeutic drugs directly to lung tumors, reducing systemic side effects and potentially improving treatment efficacy.
GENE
THERAPY
19,200 STUDIES
Facilitates inhaled gene delivery, offering new possibilities for genetic lung disease treatments.
Why Choose trū
Chitosan Inhalant?
trū Chitosan USP Inhalant is produced in an FDA registered facility under cGMP’s and the only chitosan that meets the USP-NF and USP 232 purity standards for inhaled delivery for pharmaceutical applications.
FIRST AND ONLY
GMP chitosan that meets USP 232 inhalation delivery standards for impurities
PRODUCED AT SCALE
Vertically integrated, linear homogeneous production, tissue to chitin to chitosan, with no blending ever insuring lot-to-lot consistency and behavior.
GLOBAL PHARMACEUTICAL & RESEARCH PARTNER
Ever growing list of medical applications by leading global pharmaceutical and medical device organizations that recognize the quality and consistency of trū Chitosan. Come join us!